Passive transfer of a monoclonal antibody (MAb) specific for glycoprotein D (gD) is highly effective in preventing the development of herpes simplex virus type 1-induced stromal keratitis. In the present study, we investigated whether animals which had been functionally depleted of T-cell subsets or asialo GM1+ cells would continue to be responsive to MAb therapy. BALB/c mice were depleted of CD4+, CD8+, or asialo GM1+ cells by treatment with anti-L3T4, anti-Lyt 2.2, or anti-asialo GM1 antibodies, respectively. Functional depletion of CD4+ cells was documented by the loss of delayed-type hypersensitivity responsiveness, while CD8+ cell depletion was accompanied by abrogation of cytotoxic lymphocyte activity. Anti-asialo GM1 treatment led to the loss of natural killer cell lytic activity. Mice depleted of the desired cell population and infected on the scarified cornea with herpes simplex virus type 1 uniformly developed necrotizing stromal keratitis by 3 weeks postinfection. A single inoculation of anti-gD MAb (55 ,ug) given intraperitoneally 24 h postinfection strongly protected hosts depleted of CD4+ cells against stromal keratitis. Likewise, antibody treatment in CD8+ or asialo GM1+ cell-depleted hosts was as therapeutically effective as that seen in non-cell-depleted mice. We also observed that in cell-depleted mice, the virus spread into the central nervous system and caused encephalitis. The CD4+ cell-depleted mice were the most severely affected, as 100% developed fatal disease. Anti-gD MAb treatment successfully protected all (32 of 32) CD4+-, CD8+-, or asialo GM1-depleted hosts against encephalitis. We therefore conclude that antibody-mediated prevention of stromal keratitis and encephalitis does not require the obligatory participation of CD4+, CD8+, or asialo GM1+ cells. However, when mice were simultaneously depleted of both CD4+ and CD8+ T-cell subsets, antibody treatment could not prevent fatal encephalitis. Thus, antibody can compensate for the functional loss of one but not two T-lymphocyte subpopulations.
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Infection of the cornea with herpes simplex virus (HSV) can induce disease ranging from mild epithelial ulcers to severe necrotizing stromal keratitis (4) . Indeed, ocular infection with HSV is regarded as the most common cause of infectious blindness in industrialized countries (17) . Murine models of herpetic stromal keratitis have been developed, and studies of the pathogenesis of the disease have been conducted with both euthymic and athymic hosts. The collective results strongly support the concept that corneal opacity is due, at least in part, to the host's T-cell immune response to virus infection (10, 19, 24, 29) .
HSV type 1 (HSV-1)-induced stromal keratitis can be prevented by the timely administration of monoclonal antibodies (MAbs) specific for the major glycoproteins of the virus (15, 20) . However, the mechanism by which passively transferred MAb protects against blinding corneal opacity is not known. It seems unlikely that protection is due solely to neutralization of cell-free virus or antibody-mediated lysis of virus-infected cells, because antibody treatment did not result in rapid virus clearance from the eye (15) . In fact, it has been shown that MAbs lacking virus-neutralizing or antibody-dependent cellular cytotoxicity activities can be protective (28) . Since HSV-sensitized T cells appear to be needed for the development of stromal keratitis (10, 24) , we postulated that passive transfer of antibody protected against this disease because it prevented T-cell sensitization.
However, subsequent investigation established that the generation of immune T cells to virus antigens was not suppressed (16) . On the contrary, delayed-type hypersensitivity (DTH) responsiveness to HSV-1 antigens was accelerated.
In BALB/c mice, DTH to HSV antigen is mediated by the CD4+ T-cell subset (24) . One possibility was that the early appearance of these sensitized cells together with the antibody would favor efficient clearance of viral antigens from ocular tissue. As a consequence, corneal inflammation would be minimized. In the absence of antibody treatment, CD4+ T-cell appearance would not be accelerated and the slower emergence of these cells together with persisting virus antigen could favor an immunopathogenic response, i.e., stromal keratitis.
Accordingly, the present study was undertaken to test the foregoing scenario. The specific question investigated was whether effective antibody therapy required the active participation of HSV-sensitized CD4+ T cells. It is well known that additional types of lymphocytes, such as the CD8+ T-cell subset and natural killer (NK) cells, can lyse HSVinfected cells (2, 36) and release antiviral lymphokines such as gamma interferon (13, 34) . We therefore also investigated whether these two types of effector cells played a critical role in antibody-mediated host recovery.
The experimental approach was to selectively deplete mice of one of the above three cell types via the in vivo administration of antibody specific for the appropriate surface antigen and then assess whether cell depletion inter-fered with the MAb's capacity to prevent stromal keratitis. During the course of the experiments, it was observed that in cell-depleted hosts ocular infection was followed by migration of virus into the central nervous system (CNS). Therefore, it was also possible to determine whether lymphoid cell participation was required in order for antibody to protect against fatal encephalitis. Our results showed that regardless of which type of cell was depleted, MAb continued to protect against both ocular and CNS disease. Only when the host was depleted of both T-cell subsets did passively transferred antibody fail to prevent death.
MATERIALS AND METHODS Animals. Four-week-old female BALB/c mice were obtained from Charles River Breeding Laboratories, Wilmington, Mass.
Virus. HSV-1 strain RE, a known stromal keratitis inducer (15, 19) , was used. Virus stocks were grown and titrated on Vero cells as previously described (14) .
Corneal infection. For corneal infection, mice were anesthetized with 0.2 ml of a 1:10 dilution of sodium pentobarbital (50 mg/ml of stock solution) and one eye of each mouse was scarified by three twists of a 2-mm corneal trephine. A 2-,ul volume containing the desired concentration of HSV-1 strain RE was dropped onto the corneal surface and gently massaged into the eye with the eyelids. Eyes were examined weekly for 5 weeks in masked fashion by using a dissecting biomicroscope with a fiber optic light source. Corneal opacity was graded on a scale of 0 to +5 as described elsewhere (20) ; a score of 0 indicates a clear cornea, whereas a +5 score represents severe necrotizing stromal keratitis. Ocular opacity scores did not change significantly after day 21.
Antibodies. The anti-HSV glycoprotein D (gD) MAb 8D2 was prepared and purified as previously described (15 Lymphocyte depletion. Depletion of CD4+ or CD8+ T cells was performed by using the ascitic fluids described above. To deplete CD4+ cells, 250 ,ul of anti-CD4 ascitic fluid was given intraperitoneally (i.p.) 2 days before ocular infection.
To deplete CD8+ cells, 100 RId of anti-CD8 ascitic fluid was given i.p. 1 day before ocular infection and 1, 7, and 14 days postinfection. The effectiveness of depletion was assessed by testing for removal of functions mediated by the specific cell subsets (DTH or cell-mediated cytolysis of virus-infected cells) and by fluorescence-activated cell-sorting (FACS) analysis. Anti-asialo GM1 was diluted 1:8 in phosphate-buffered saline (PBS), and mice were given 200 ,ul i.p. 2 days before infection and 1 and 4 days postinfection. The effectiveness of anti-asialo GM1 treatment was determined by testing for a reduction in spleen cell NK activity.
DTH assay. DTH responsiveness was measured by using the ear swelling assay as previously described (14) 
RESULTS
Effect of anti-gD MAb given 1, 3, or 5 days postinfection. We investigated when after virus infection anti-gD MAb must be given in order to obtain a significant therapeutic effect. The results are shown in Fig. 1 . It can be seen that antibody given 24 h after corneal infection was highly effective (P < 0.025) at preventing stromal keratitis. This result is in agreement with previous studies (15, 20 (24) (Fig. 2) . The inflammatory response was significantly enhanced (P < 0.01) when the animals had also been treated with anti-gD MAb. These results confirm our earlier report that passively transferred antibody to gD accelerates host sensitization (16) . Figure 2 shows that a single inoculation of anti-CD4 MAb reduced DTH responsiveness in both antibody-treated and untreated HSV-1-sensitized hosts to background levels, i.e., to levels of nonspecific swelling seen in the ears of naive hosts. FACS analysis performed 6 days postinfection showed that CD4+ cells in the spleen were reduced by >95%. This alternative assay provided independent confirmation of the effectiveness of anti-CD4 treatment. The anti-CD4 treatment was selective in that the specific lysis of HSV-1-infected target cells (43%) by CD8+ cells was not abrogated. CD4+ cell depletion was transient in that DTH responsiveness was restored by day 18 postinfection (data not shown).
Effect of CD4+ cell depletion on the therapeutic effectiveness of anti-gD MAb. We next tested whether anti-gD treatment would protect against stromal keratitis in mice functionally depleted of CD4+ cells. Figure 3 shows that untreated CD4+-depleted hosts uniformly developed necrotizing stromal keratitis. Furthermore, the virus spread into the CNS and produced fatal encephalitis in all six recipients by day 18 (Table 1) . However, none of the MAb-treated mice developed severe corneal opacity or CNS disease (Fig. 3) . Thus, CD4+ T-cell participation was not required in order for the antibody to be protective.
Effect of anti-CD8 treatment on HSV-specific CTL response. It was possible that T cells of the CD8+ phenotype might play a role in antibody-mediated protection. To test Twenty-four hours later, the mice were given anti-gD MAb or IgG2a i.p. and then monitored for development of corneal opacity. There were six mice per group. CD4+ cell-depleted hosts given anti-gD MAb were significantly protected against the development of stromal keratitis (P < 0.05).
this premise, mice were depleted of this T-cell subset via anti-CD8 treatment. In vivo treatment with anti-CD8 MAb completely abrogated the subsequent generation of CTL activity in cervical lymph node cells taken from HSVinfected hosts 6 days postinfection. Specifically, cervical lymph node cells from control mice lysed HSV-infected target cells with a specific lysis of 18.0 ± 0.04%, while anti-CD8-treated mice had a specific lysis of -1.3 ± 0.4%. There was no lysis of uninfected target cells by cervical lymph node cells from either group. However, anti-CD8-treated hosts still could mount an HSV-specific DTH response (34.2 ± 1.7 x 10-4 in. [1 in. = 2.54 cm]). FACS analysis indicated that the number of CD8+ cells in the spleen was reduced by 85% and that this level of depletion persisted through day 21 postinfection (data not shown).
Effect of CD8+ T-cell depletion on the therapeutic effectiveness of anti-gD MAb. Mice functionally depleted of CD8+ T cells were infected on the cornea with HSV-1 and given Days Post Infection  FIG. 4 . Effect of CD8+ cell depletion on the capacity of anti-gD MAb to protect against HSV-1-induced stromal keratitis. Anti-CD8-treated and untreated mice were infected on the cornea with 2 x 104 PFU of HSV-1. Mice were given anti-gD MAb or IgG2a i.p. 24 h later and then monitored for the development of corneal opacity. There were six mice in each group. CD8+ cell-depleted hosts given anti-gD MAb were significantly protected against stromal keratitis (P < 0.005).
anti-gD MAb 24 h later. Figure 4 shows that anti-CD8 treatment did not impair the antibody's protective effects, as the opacity scores were not significantly different from those for the T-cell-intact, antibody-treated animals. It is also evident that CD8+ cell depletion did not interfere with the development of stromal keratitis in the untreated hosts. Two of six CD8+-deficient mice died of CNS disease, whereas none of the anti-gD-treated hosts developed encephalitis (Table 1 ). These results indicated that the CD8+ T-cell subset was not required in order for the antibody to protect against corneal disease or encephalitis.
Loss of anti-gD MAb protective effect in mice depleted of both CD4+ and CD8+ T cells. Ocular infection of mice simultaneously depleted of CD8+ and CD4+ cells resulted in the deaths of all animals due to encephalitis (Table 1) . Passively transferred anti-gD MAb did not prevent death (Table 1) , although it did significantly (P < 0.001) increase the mean survival time from 9 to 19 days. The mean ocular opacity score in anti-gD-treated, T-cell-depleted mice (1.33 + 0.56) was significantly lower (P < 0.005) than that seen in T-cell-intact control mice (4.5 + 0.22) at 18 days postinfection. However, since all untreated T-cell-depleted controls had died, it was not possible to determine whether the reduced ocular disease in the T-cell-depleted mice was due to the lack of CD4+ cells, to the effect of the anti-gD MAb, or to a combination of both.
Effect of asialo GM1+ cell depletion on the therapeutic effectiveness of anti-gD MAb. Rabbit anti-asialo GM1 serum was used to selectively deplete mice of those cells, including NK cells, which express this antigen. HSV-1-infected mice given this antiserum had no NK lytic activity in their spleen cells 7 days postinfection, whereas the lytic activity in the spleen cells of untreated infected animals was 8% (P < 0.04). Additional evidence that functional depletion had occurred was provided by the finding that the GM1+ cell-depleted hosts exhibited increased susceptibility to HSV-1 corneal infection. Four of eight mice died with encephalitis by day 10 (Table 1) , and all surviving animals developed necrotizing stromal keratitis. We found that anti-gD MAb treatment in GM1+-depleted hosts was as effective as that seen in antibody-treated GM1+ cell-intact animals ( Fig. 5 and Table 1 Anti-asialo GM1-treated and untreated mice were infected with 5 x 104 PFU of HSV-1. Mice were given anti-gD MAb or IgG2a i.p. 24 h later and then monitored for the development of corneal opacity. There were eight mice in each group. Asialo GM1+ cell-depleted hosts given anti-gD MAb were significantly protected against stromal keratitis (P < 0.005).
collaborate with asialo GM1 + cells in order to protect against stromal keratitis or CNS disease.
DISCUSSION
Passively transferred MAbs to the major glycoproteins of HSV-1 are remarkably effective at preventing virus-induced stromal keratitis (15, 20) . The present study was designed to probe the protective mechanism(s). Specifically, we investigated whether the participation of selected lymphocyte subsets was required in order for the antibody to exert its protective effect. We show here that functional depletion of CD4+, CD8+, or asialo GM1+ cells did not abrogate anti-gD therapy. In fact, antibody treatment in the cell-depleted mice prevented stromal keratitis just as efficiently as in hosts with an intact lymphocyte population. Furthermore, the capacity for antibody to prevent CNS disease also continued unabated in lymphocyte-subset-depleted hosts.
In conducting this work, it was important to establish that functional depletion of the desired lymphocyte population had been achieved. Evidence for CD4+ cell depletion was provided by the demonstration that DTH responsiveness to HSV-1 antigen was abrogated during the first week postinfection, i.e., the time during which putative T-cell-MAb collaboration would be expected to occur (Fig. 1) . Since stromal keratitis development in the BALB/c mouse appears to require CD4+ cells (24) , it was also important that depletion be transient in nature. Accordingly, only a single treatment with anti-L3T4 was used. Indeed, it was found that CD4+ cell-depleted hosts which survived to day 14 postinfection did develop necrotizing stromal keratitis and that positive DTH tests could be elicited (unpublished observations). Thus, we can conclude that the absence of stromal disease in the depleted mice was due to antibodymediated protection and not because there were insufficient CD4+ T cells to induce inflammation.
Although transient depletion of CD4+ T cells did not abrogate the development of herpes stromal keratitis, it greatly increased host susceptibility to CNS disease following HSV-1 corneal infection. None of the CD4+ cell-depleted mice survived to 3 weeks postinfection, whereas 94% of T-cell-intact mice survived (Table 1) . This result, which provides further evidence of functional CD4+ T-cell depletion, supports the view that CD4+ cells play a critical role in CNS resistance to HSV-1 infection (22, 23, 25) . Curiously, in certain other studies (6, 24) Prolonged depletion of CD8+ cells, the other major T-lymphocyte subset, also failed to interfere with the capacity of anti-gD MAb to prevent stromal keratitis or encephalitis.
Evidence for effective functional depletion of these T cells was provided by the finding of increased host susceptibility to CNS disease as well as the abrogation of CTL activity in vitro. The role that CD8+ T cells play in herpes stromal keratitis has been controversial. These cells have been reported to be protective in BALB/c mice infected with the RE strain of HSV-1, as their selective depletion resulted in increased severity of ocular disease (24) . In contrast, this T-cell subset was found to contribute to the immunopathological process in the eyes of A/J mice infected with HSV-1 strain KOS (10) . Recent studies indicate that the role which this T-cell subset plays in stromal disease is apparently influenced by the strain of virus used for infection (9, 11) . We found that vigorous inflammatory reactions occurred in untreated, cell-depleted mice. This supports the view that CD8+ cells are not needed for the development of corneal opacity after HSV-1(RE) infection.
Asialo GM1, a glycosphingolipid, is a component of the NK cell membrane. Although this antigen is not entirely restricted to this lymphocyte subset, it is these cells which appear to be primarily depleted by anti-asialo GM1 treatment (32, 34) . In the present study, we found that NK cell-depleted hosts developed necrotizing stromal keratitis and became significantly more susceptible to CNS disease following HSV-1 corneal challenge. The former observation suggests that NK cells are not required for the development of ocular inflammation. The latter results agree with the view that asialo GM1+ cells contribute to host resistance to HSV-1 infection, a concept for which there has been both support (7, 18, 27) and disagreement (1, 3, 33) . Administration of anti-gD MAb to asialo GM1+ cell-depleted hosts proved to be strikingly effective in that both stromal and CNS disease were prevented. Thus, analogous to the T-cell depletion results, functional asialo GM1+ cell depletion does not compromise effective anti-HSV serotherapy.
Our study does not rule out the possibility that cells other than those tested may participate in the protective mechanism of anti-gD MAb. However, the present results do not provide support for the hypothesis that antibody and T cells or NK cells collaborate to prevent blinding stromal disease. It is of special interest that little or no histological (unpublished observations) or clinical evidence of inflammation was noted in the cornea despite the fact that vigorous DTH responses to HSV antigens could be elicited systemically. Collectively, our observations raise the intriguing prospect that antibody may prevent stromal keratitis by somehow disrupting the early signals that trigger ocular inflammation. Such a hypothesis would be compatible with the narrow therapeutic window observed for antibody treatment. Efforts are under way to investigate this premise.
We also investigated the effect depletion of both T-cell subsets would have on antibody-mediated protection. It was found that mice depleted of both CD4+ and CD8+ T cells displayed greatly increased vulnerability to HSV-1-induced encephalitis, so much so that none survived longer than 11 days postinfection. Under these conditions, antibody therapy delayed, but did not prevent, death. Six of the anti-gD- (12) .
